All Stories

  1. The future of pleiotropic therapy in heart failure. Lessons from the benefits of exercise training on endothelial function
  2. Cardiac endothelium–myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction
  3. Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4
  4. Is overemphasizing diastolic dysfunction in heart failure with a preserved ejection fraction too narrow minded?
  5. Pathophysiology of diastolic dysfunction in chronic heart failure
  6. Therapeutic potential of neuregulin-1 in cardiovascular disease
  7. Cardiotoxicidade associada à terapêutica oncológica: mecanismos fisiopatológicos e estratégias de prevenção
  8. Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention
  9. Pathophysiology of Heart Failure: Back to Basics
  10. Impact of Radiofrequency Characteristics on Acute Pulmonary Vein Reconnection and Clinical Outcome After PVAC Ablation
  11. Molecular Mechanisms of Cardiotoxicity Induced by ErbB Receptor Inhibitor Cancer Therapeutics
  12. Pulmonary hypertension and right heart failure in heart failure with preserved left ventricular ejection fraction
  13. Effect of a telemonitoring‐facilitated collaboration between general practitioner and heart failure clinic on mortality and rehospitalization rates in severe heart failure: the TEMA‐HF 1 (TElemonitoring in the MAnagement of Heart Failure) study
  14. Effects of the long‐term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study
  15. Effects of Nebivolol on Vascular Endothelial and Myocardial Function in Diabetes Mellitus
  16. Systolic and Diastolic Heart Failure Are Overlapping Phenotypes Within the Heart Failure Spectrum
  17. Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries
  18. HEART FAILURE WITH A PRESERVED EJECTION FRACTION: FROM PATHOPHYSIOLOGY TO BIOMARKERS … AND BEYOND!
  19. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology
  20. Pulmonary vein stenosis after pulmonary vein ablation catheter–guided pulmonary vein isolation
  21. Role of autophagy in heart failure associated with aging
  22. Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study
  23. The Heart Failure Spectrum
  24. Ventricular ErbB2/ErbB4 activation and downstream signaling in pacing-induced heart failure
  25. Chapter 9 Chronic heart failure with preserved ejection fraction
  26. Molecular Mechanisms of Diastolic Dysfunction
  27. Normal Physiology and Pathophysiology of Left Ventricular Diastole
  28. Heart Failure with Preserved Ejection Fraction
  29. Evidence that intracoronary-injected CD133+ peripheral blood progenitor cells home to the myocardium in chronic postinfarction heart failure
  30. Endothelial function in aorta segments of apolipoprotein E-deficient mice before development of atherosclerotic lesions
  31. Endogenous inhibitors of hypertrophy in concentric versus eccentric hypertrophy
  32. Systolic and diastolic heart failure: Different phenotypes of the same disease?
  33. Pathophysiology and Clinical Impact of Diastolic Heart Failure
  34. Diastolic Heart Failure: A Separate Disease or Selection Bias?
  35. Diastolic heart failure: a myth
  36. Cardiomyopathy and thyrotoxicosis
  37. Urgent need to reorganize heart failure management
  38. The Endocardial Endothelial Na+/K+Atpase and Cardiac Contraction
  39. Identification of IEX-1 as a Biomechanically Controlled Nuclear Factor-κB Target Gene That Inhibits Cardiomyocyte Hypertrophy
  40. Dilated Cardiomyopathy: Changing PathophysiologicaI Concepts and Mechanisms of Dysfunction
  41. Reappraisal of the Multicellular Preparation for the In Vitro Physiopharmacological Evaluation of Myocardial Performance
  42. Endocardial—Myocardial Interaction
  43. Endocardial endothelial dysfunctionand heart failure
  44. Sensibilisation du coeur endotoxinique aux effets inotropes de lendotheline
  45. Dilated Cardiomyopathy: Changing PathophysiologicaI Concepts and Mechanisms of Dysfunction